Table 31:

Recommendation for roxadustat as an alternative to ESA for DD-CKD patients

Recommendation for use in research setting only	This recommendation is evidence informed.
Roxadustat should not be used for DD-CKD patients, except in the context of an approved randomized controlled trial. The panel recommends conducting large head-to-head multicentric randomized controlled trials in the South Asian region on DD-CKD patients and measuring critically important outcomes (as elucidated in this guideline) such that evidence base for roxadustat is improved.

DD: Dialysis-Dependent, CKD: Chronic kidney disease, ESA: Eythropoiesis-stimulating agents